Journal of General Internal Medicine

, Volume 22, Issue 3, pp 321–326

The Impact of Venous Thromboembolism on Risk of Death or Hemorrhage in Older Cancer Patients

  • Cary P. Gross
  • Deron H. Galusha
  • Harlan M. Krumholz
Original Article

Background

Among older cancer patients, there is uncertainty about the degree to which venous thromboembolism (VTE) and its treatment increase the risk of death or major hemorrhage.

Objective

To determine the prevalence of VTE in a cohort of older cancer patients, as well as the degree to which VTE increased the risk of death or major hemorrhage.

Methods

We conducted a retrospective cohort study of linked Surveillance, Epidemiology, and End Results cancer registry and Medicare administrative claims data. Patients with any of ten invasive cancers diagnosed during 1995 through 1999 were included; the independent variable was VTE diagnosed concomitantly with cancer diagnosis. Outcomes included major hemorrhage during the first year after cancer diagnosis and all-cause mortality;

Results

Overall, about 1% of patients who were diagnosed with cancer also had a VTE diagnosed concomitantly. After adjusting for sociodemographic factors and cancer stage and grade, concomitant VTE was associated with a relative increase in the risk of death for 8 of the 10 cancer types; the increase in risk tended to range 20–40% across most cancer types. Approximately 16.8% (95% confidence interval [CI] 14.9–18.8%) of patients with a concomitant VTE and 7.9% (95% CI 7.7–8.0%) of patients without a VTE experienced a major hemorrhage during the year after cancer diagnosis (P value <.001). The excess risk of hemorrhage associated with VTE varied substantially across cancer types, ranging from no significant excess (kidney and uterine cancer) to 11.5% (lymphoma).

Conclusion

Concomitant VTE is not only a marker and potential mediator of increased risk of death among older cancer patients, but patients with a VTE have a marked increased risk of major hemorrhage.

Key words

thrombosis cancer hemorrhage epidemiology 

References

  1. 1.
    Levitan N, Dowlati A, Remick S, et al. Rates of initial and recurrent thromboemboloic disease among patients with malignancy versus those without malignancy. Medicine. 1999;78:285–91.PubMedCrossRefGoogle Scholar
  2. 2.
    Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107(23 suppl 1):I17–21.PubMedGoogle Scholar
  3. 3.
    Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846–50.PubMedCrossRefGoogle Scholar
  4. 4.
    Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484–8.PubMedCrossRefGoogle Scholar
  5. 5.
    White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23 suppl 1):I4–8.PubMedGoogle Scholar
  6. 6.
    Stein PD, Hull RD, Kayali F, Ghali WA, Alshab AK, Olson RE. Venous thromboembolism according to age: the impact of an aging population. Arch Intern Med. 2004;164(20):2260–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Hutchins L, Unger J, Crowley J, Coltman C, Albain K. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Ries L, Eisner M, Kosary C, et al. SEER Cancer Statistics Review, 1975–2002. National Cancer Institute. Accessed 28 Feb 2006.Google Scholar
  9. 9.
    Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715–22.PubMedCrossRefGoogle Scholar
  10. 10.
    Lee AY. Epidemiology and management of venous thromboembolism in patients with cancer. Thromb Res. 2003;110(4):167–72.PubMedCrossRefGoogle Scholar
  11. 11.
    Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78(5):285–91.CrossRefGoogle Scholar
  12. 12.
    Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458–64.PubMedCrossRefGoogle Scholar
  13. 13.
    Kearon C. Long-term management of patients after venous thromboembolism. Circulation. 2004;110(9 suppl 1):I10–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348(15):1425–34.PubMedCrossRefGoogle Scholar
  15. 15.
    Willey VJ, Bullano MF, Hauch O, et al. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clin Ther. 2004;26(7):1149–59.PubMedCrossRefGoogle Scholar
  16. 16.
    Ost D, Tepper J, Mihara H, Lander O, Heinzer R, Fein A. Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA. 2005;294(6):706–15.PubMedCrossRefGoogle Scholar
  17. 17.
    Rogers LR. Cerebrovascular complications in cancer patients. Neurol Clin. 2003;21(1):167–92.PubMedCrossRefGoogle Scholar
  18. 18.
    Wells PS, Forgie MA, Simms M, et al. The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med. 2003;163(8):917–20.PubMedCrossRefGoogle Scholar
  19. 19.
    Miller B, Ries L, Hankey B, eds. Cancer Statistics Review 1973–89. Bethesda, MD: NIH; 1992. Institute NC, ed; No. 92–2789.Google Scholar
  20. 20.
    Potosky A, Riley G, Lubitz J, Mentnech R, Kessler L. Potential for cancer related health services research using a linked Medicare–tumor related database. Med Care. 1993;31:732–48.PubMedCrossRefGoogle Scholar
  21. 21.
    National Cancer Institute. SEER–Medicare: Brief Description of the SEER–Medicare Database. ed: http://healthservices.cancer.gov/seermedicare/overview//. Accessed 7 Aug 2006.
  22. 22.
    Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M. Venous thromboembolism and cancer. Lancet. 1998;351(9109):1077–80.PubMedCrossRefGoogle Scholar
  23. 23.
    White RH, Chew HK, Zhou H, et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med. 2005;165(15):1782–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Brass L, Lichtman J, Wang Y, Gurwitz J, Radford M, Krumholz H. Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction. Stroke. 2000;31:1802–11.PubMedGoogle Scholar
  25. 25.
    Baker DW, Einstadter D, Thomas CL, Husak SS, Gordon NH, Cebul RD. Mortality trends during a program that publicly reported hospital performance. Med Care. 2002;40(10):879–90.PubMedCrossRefGoogle Scholar
  26. 26.
    Lamont EB, Lauderdale DS, Schilsky RL, Christakis NA. Construct validity of medicare chemotherapy claims: the case of 5FU. Med Care. 2002;40(3):201–11.PubMedCrossRefGoogle Scholar
  27. 27.
    Schrag D, Gelfand SE, Bach PB, Guillem J, Minsky BD, Begg CB. Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results—Medicare. J Clin Oncol. 2001;19(17):3712–8.PubMedGoogle Scholar
  28. 28.
    Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53(12):1258–67.PubMedCrossRefGoogle Scholar
  29. 29.
    Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000;18(17):3078–83.PubMedGoogle Scholar
  30. 30.
    Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105(2):91–9.PubMedCrossRefGoogle Scholar
  31. 31.
    White RH, Gettner S, Newman JM, Trauner KB, Romano PS. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med. 2000;343(24):1758–64.PubMedCrossRefGoogle Scholar
  32. 32.
    Hsia DC, Krushat WM, Fagan AB, Tebbutt JA, Kusserow RP. Accuracy of diagnostic coding for Medicare patients under the prospective-payment system. N Engl J Med. 1988;318(6):352–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Kniffin WD, Jr., Baron JA, Barrett J, Birkmeyer JD, Anderson FA, Jr. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med. 1994;154(8):861–6.PubMedCrossRefGoogle Scholar
  34. 34.
    FDA. FDA Website. http://www.fda.gov/medwatch/safety/1998/dec98.htm#loveno. Accessed 15 Jul 2005.

Copyright information

© Society of General Internal Medicine 2007

Authors and Affiliations

  • Cary P. Gross
    • 1
    • 3
    • 5
  • Deron H. Galusha
    • 5
  • Harlan M. Krumholz
    • 2
    • 3
    • 4
    • 5
  1. 1.Section of General Internal MedicineYale University School of MedicineNew HavenUSA
  2. 2.Section of Cardiovascular MedicineYale University School of MedicineNew HavenUSA
  3. 3.Robert Wood Johnson Clinical Scholars ProgramYale University School of MedicineNew HavenUSA
  4. 4.Department of Epidemiology and Public HealthYale University School of MedicineNew HavenUSA
  5. 5.Center for Outcomes Research and EvaluationYale New Haven HospitalNew HavenUSA

Personalised recommendations